A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19

Camostat mesylate, an oral serine protease inhibitor, is used to treat chronic pancreatitis and reflux esophagitis. Recently, camostat mesylate and its active metabolite 4‐(4‐guanidinobenzoyloxy)phenylacetic acid (GBPA) were reported to inhibit the infection of cells by severe acute respiratory synd...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitagawa, Junsaku, Arai, Hayato, Iida, Hiroyuki, Mukai, Jiro, Furukawa, Kenji, Ohtsu, Seitaro, Nakade, Susumu, Hikima, Tomohiro, Haranaka, Miwa, Uemura, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239543/
https://www.ncbi.nlm.nih.gov/pubmed/33982445
http://dx.doi.org/10.1111/cts.13052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239543/
https://www.ncbi.nlm.nih.gov/pubmed/33982445
http://dx.doi.org/10.1111/cts.13052

Ejemplares similares